Author:
Fabrizi Fabrizio,Dixit Vivek,Messa Piergiorgio,Martin Paul
Publisher
Springer Science and Business Media LLC
Reference67 articles.
1. Finelli L, Miller JT, Tokars J, Alter MJ, Arduino M. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18:52–61.
2. Burdick R, Bregg-Gresham J, Woods J, Hedderwick S, Kurokawa K, Combe C, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2003;63:2222–9.
3. Hiesse C, Buffet C, Neyrat N, et al. Impact of HBs antigenemia on long-term patient survival and causes of death after renal transplantation. Clin Transplant. 1992;46:461–7.
4. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257–63.
5. Chan TM, Fang G, Tang CS, Cheng I, Lai KN, Ho SK. Pre-emptive lamivudine therapy based on HBV DNA level in HBsAg positive kidney allograft recipients. Hepatology. 2002;36:1246–52.